OpGen, Inc. (OPGN)
| Market Cap | 90.31M |
| Revenue (ttm) | 4.21M |
| Net Income (ttm) | -26.21M |
| Shares Out | 15.80M |
| EPS (ttm) | -1.66 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 12 |
| Last Price | $2.25 |
| Previous Close | $2.27 |
| Change ($) | -0.02 |
| Change (%) | -0.88% |
| Day's Open | 2.27 |
| Day's Range | 2.23 - 2.42 |
| Day's Volume | 814,618 |
| 52-Week Range | 1.63 - 4.44 |
OpGen, Inc. (OPGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GAITHERSBURG, Md., April 29, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its first quarter 2...
GAITHERSBURG, Md., April 19, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today that its strategic collaboration with the New York State Department of Health (“DOH”) to develop a state-...
Experts presented the results of their Unyvero studies and demonstrated:
OpGen, Inc. (OPGN) delivered earnings and revenue surprises of -20.69% and 4.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
OpGen, Inc. (OPGN) delivered earnings and revenue surprises of -6.90% and 4.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Conference call to be held at 4:30 p.m. Eastern Time today
OpGen (NASDAQ:OPGN) unveils its next round of earnings this Thursday, March 25. Get prepared with Benzinga's ultimate preview for OpGen's Q4 earnings.
OpGen, Inc. (OPGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GAITHERSBURG, Md., March 11, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its fourth quarter ...
Immunovant, Inc. (NASDAQ: IMVT), Anchiano Therapeutics Ltd. (NASDAQ: ANCN) and OpGen, Inc. (NASDAQ: OPGN) are among the biggest healthcare gainers on Monday.
OpGen (OPGN) stock is flying high on Monday following results from a study published in a peer-reviewed publication concerning coronavirus. The post OPGN Stock: 9 Things for OpGen Investors to Know as S...
Karolinska Institutet Study highlights Unyvero HPN demonstrating a higher diagnostic yield than bacterial culture, enabling rapid diagnosis of pathogens of concern in these patients
GAITHERSBURG, Md., March 01, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat in...
Study highlights best practice techniques for accurate antimicrobial resistance prediction from whole-genome sequencing data
GAITHERSBURG, Md., Jan. 13, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat inf...
GAITHERSBURG, Md. and HOLZGERLINGEN, Germany, Jan. 05, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinf...
Dr. Arne Materna to join Ares Genetics as new Managing Director and CEO to lead Ares into next phase of its growth
Extended collaboration with leading global generics company Sandoz for optimal antibiotic drug positioning by predictive antibiotic susceptibility testing
GAITHERSBURG, Md., Nov. 24, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat inf...
Early access program launched for the next generation of the ARESupa Universal Pathogenome Assay based on targeted next-generation sequencing (NGS) of native specimens
OpGen, Inc. (OPGN) CEO Oliver Schacht on Q3 2020 Results - Earnings Call Transcript
Conference call to be held at 4:30 p.m. Eastern Time today
GAITHERSBURG, Md., Oct. 29, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its third quarter 20...
OpGen Announces Award of German Government Grant Funding to its Subsidiary Curetis and Collaborators
GAITHERSBURG, Md. and HOLZGERLINGEN, Germany, Oct. 28, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinf...
GAITHERSBURG, Md., Oct. 15, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat inf...
GAITHERSBURG, Md., Oct. 13, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat inf...
Ares Genetics wins Austrian Digitization Award for Digital Products and Solutions
GAITHERSBURG, Md. and HOLZGERLINGEN, Germany, Sept. 28, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bio...
GAITHERSBURG, Md., Sept. 18, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”) announced today that it has changed the venue of its 2020 Annual Meeting of Stockholders due ...
Published Study on Modifiable Risk Factors for the Emergence of Ceftolozane-Tazobactam Resistance
Ares Genetics nominated for the 40th Austrian Innovation Award by Federal Ministry for Digital and Economic Affairs
GAITHERSBURG, Md., and HOLZGERLINGEN, Germany, Sept. 02, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bi...
OpGen (NASDAQ: OPGN) shares are trading higher after the company announced its subsidiary obtained the CE mark certification in the European Union for its own SARS-CoV-2 Kit with PULB detection of SARS-...
Shares of Maryland-based OpGen Inc. OPGN, -0.96% rocketed 43% in active premarket trading Thursday, after the molecular diagnostics company said its Germany-based Curetis GmbH subsidiary obtained the CE...
- Own developed SARS-CoV-2 Kit with PULB for COVID-19 uses real-time PCR (RT-PCR) technology on open PCR platforms, designed to provide results in approximately one hour
OpGen, Inc. (OPGN) CEO Oliver Schacht on Q2 2020 Results - Earnings Call Transcript
Shares of OpGen (NASDAQ:OPGN) rose 4.98% in after-market trading after the company reported Q2 results.
Conference call to be held at 4:30 p.m. Eastern Time today
OpGen (NASDAQ: OPGN) will be releasing its next round of earnings this Wednesday, August 12.
Accurate identification of antibiotic resistance markers based on the ARESdb QIAGEN CLC Module leveraging Ares Genetics’ proprietary antibiotic resistance database
GAITHERSBURG, Md., Aug. 09, 2020 (GLOBE NEWSWIRE) -- As disclosed in OpGen, Inc.’s (NASDAQ: OPGN) (“OpGen” or “the Company”) July 13, 2020 press release, we have commenced marketing and promotion, on ...
GAITHERSBURG, Md., Aug. 05, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter...
GAITHERSBURG, Md., July 15, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN)(“OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infe...
Strategic partnership will focus on commercializing CELLSEARCH platform for COVID-19 related use cases, along with other COVID-19 related products Strategic partnership will focus on commercializing CEL...
- European Investment Bank (EIB) and OpGen, Curetis GmbH and Ares Genetics GmbH enter into Amendment to the EIB Financing Agreement
If you’re looking for some hedges for your portfolio or are looking to shift against the market, our deep learning algorithms and AI technology have several Top Shorts for you today.
OpGen (NASDAQ: OPGN) shares are trading higher after the company announced its Unyvero HPN Panel identifies bacterial co-infections in hospitalized patients with COVID-19 pneumonia in just five hours.
GAITHERSBURG, Md. and HOLZGERLINGEN, Germany, June 09, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioi...
GAITHERSBURG, Md., May 11, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infec...
About OPGN
OpGen, Inc., a precision medicine company, engages in developing molecular information products and services in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel, a vitro diagnostic test for the detection and identification o... [Read more...]
| Industry Diagnostics & Research | IPO Date May 5, 2015 |
| CEO Oliver Schacht | Employees 94 |
| Stock Exchange NASDAQ | Ticker Symbol OPGN |
Financial Performance
In 2020, OpGen, Inc.'s revenue was $4.21 million, an increase of 20.46% compared to the previous year's $3.50 million. Losses were -$26.21 million, 110.6% more than in 2019.
Analyst Forecasts
According to 2 analysts, the average rating for OpGen, Inc. stock is "Buy." The 12-month stock price forecast is 5.50, which is an increase of 144.44% from the latest price.